$SNDX
Syndax Pharmaceuticals Inc

2024 Q2 Form 10-Q Financial Statement

#000095017024055053 Filed on May 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $3.500M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $29.06M $23.02M
YoY Change 95.04% 92.48%
% of Gross Profit
Research & Development $48.66M $56.49M
YoY Change 39.96% 65.89%
% of Gross Profit
Depreciation & Amortization $3.000K $3.000K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $77.72M $79.51M
YoY Change 56.44% 72.8%
Operating Profit -$74.22M -$79.51M
YoY Change 49.39% 72.8%
Interest Expense $45.00K $55.00K
YoY Change 28.57% 37.5%
% of Operating Profit
Other Income/Expense, Net $6.153M $7.114M
YoY Change 21.53% 45.51%
Pretax Income -$53.20M -$72.40M
YoY Change 19.29% 76.04%
Income Tax
% Of Pretax Income
Net Earnings -$68.06M -$72.40M
YoY Change 52.56% 76.04%
Net Earnings / Revenue -1944.66%
Basic Earnings Per Share -$0.80 -$0.85
Diluted Earnings Per Share -$0.80 -$0.85
COMMON SHARES
Basic Shares Outstanding 84.99M 84.97M
Diluted Shares Outstanding 85.27M 85.21M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $432.3M $443.2M
YoY Change 6.46% 1.13%
Cash & Equivalents $105.4M $114.6M
Short-Term Investments $326.9M $328.5M
Other Short-Term Assets $9.582M $6.073M
YoY Change 279.94% 392.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $446.1M $453.9M
YoY Change 9.04% 2.81%
LONG-TERM ASSETS
Property, Plant & Equipment $2.000K $5.000K
YoY Change -99.9% -70.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $29.52M $87.42M
YoY Change 51.5% 427.84%
Other Assets $156.0K $248.0K
YoY Change -80.4% -64.21%
Total Long-Term Assets $30.89M $89.13M
YoY Change 38.77% 386.64%
TOTAL ASSETS
Total Short-Term Assets $446.1M $453.9M
Total Long-Term Assets $30.89M $89.13M
Total Assets $476.9M $543.0M
YoY Change 10.57% 18.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.57M $8.809M
YoY Change 5.37% 9.33%
Accrued Expenses $27.79M $34.44M
YoY Change 48.72% 119.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $12.00K $12.00K
YoY Change 9.09% 140.0%
Total Short-Term Liabilities $42.47M $50.81M
YoY Change 40.78% 114.18%
LONG-TERM LIABILITIES
Long-Term Debt $4.000K $7.000K
YoY Change -75.0% -41.67%
Other Long-Term Liabilities $133.0K $327.0K
YoY Change -88.07% -44.39%
Total Long-Term Liabilities $137.0K $334.0K
YoY Change -87.89% -44.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.47M $50.81M
Total Long-Term Liabilities $137.0K $334.0K
Total Liabilities $42.61M $51.14M
YoY Change 36.14% 110.27%
SHAREHOLDERS EQUITY
Retained Earnings -$1.043B -$974.8M
YoY Change 33.91% 32.78%
Common Stock $1.478B $1.467B
YoY Change 25.32% 25.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $434.3M $491.9M
YoY Change
Total Liabilities & Shareholders Equity $476.9M $543.0M
YoY Change 10.57% 18.09%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$68.06M -$72.40M
YoY Change 52.56% 76.04%
Depreciation, Depletion And Amortization $3.000K $3.000K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$71.65M -$83.55M
YoY Change 102.55% 112.98%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $61.75M -$99.40M
YoY Change -16.45% -599.12%
Cash From Investing Activities $61.75M -$99.40M
YoY Change -16.45% -599.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 676.0K 2.168M
YoY Change -48.94% -12.37%
NET CHANGE
Cash From Operating Activities -71.65M -83.55M
Cash From Investing Activities 61.75M -99.40M
Cash From Financing Activities 676.0K 2.168M
Net Change In Cash -9.219M -180.8M
YoY Change -123.13% 973.57%
FREE CASH FLOW
Cash From Operating Activities -$71.65M -$83.55M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001395937
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 sndx Depreciation And Related Adjustment
DepreciationAndRelatedAdjustment
3000
CY2023Q1 sndx Depreciation And Related Adjustment
DepreciationAndRelatedAdjustment
3000
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3821000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3967000
CY2024Q1 sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
244000
CY2023Q1 sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
110000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8899000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6238000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2854000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2899000
CY2024Q1 sndx Increase Decrease In Collaboration Receivable Payable
IncreaseDecreaseInCollaborationReceivablePayable
315000
CY2023Q1 sndx Increase Decrease In Collaboration Receivable Payable
IncreaseDecreaseInCollaborationReceivablePayable
2082000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
6073000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
0
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1152000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3707000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6709000
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-37708
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Syndax Pharmaceuticals, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0162505
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
35 Gatehouse Drive
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Building D
CY2024Q1 dei Entity Address Address Line3
EntityAddressAddressLine3
Floor 3
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
CY2024Q1 dei City Area Code
CityAreaCode
781
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
419-1400
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2024Q1 dei Trading Symbol
TradingSymbol
SNDX
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
84987060
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114615000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
295394000
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
319963000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
275304000
CY2024Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
8583000
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
6885000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
6073000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
0
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4665000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3293000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
453899000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
580876000
CY2024Q1 us-gaap Long Term Investments
LongTermInvestments
87416000
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
29829000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1243000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1487000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
217000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
217000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
248000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
463000
CY2024Q1 us-gaap Assets
Assets
543028000
CY2023Q4 us-gaap Assets
Assets
612880000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
8809000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9961000
CY2024Q1 sndx Collaboration Payable Current
CollaborationPayableCurrent
7547000
CY2023Q4 sndx Collaboration Payable Current
CollaborationPayableCurrent
7232000
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
33395000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
39856000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1042000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1035000
CY2024Q1 sndx Current Portion Of Capital Lease
CurrentPortionOfCapitalLease
12000
CY2023Q4 sndx Current Portion Of Capital Lease
CurrentPortionOfCapitalLease
12000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
50805000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
58096000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
327000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
578000
CY2024Q1 sndx Capital Lease Less Current Portion
CapitalLeaseLessCurrentPortion
7000
CY2023Q4 sndx Capital Lease Less Current Portion
CapitalLeaseLessCurrentPortion
10000
CY2024Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
334000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
588000
CY2024Q1 us-gaap Liabilities
Liabilities
51139000
CY2023Q4 us-gaap Liabilities
Liabilities
58684000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84979686
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84979686
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84826632
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84826632
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1467437000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1456370000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-756000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
218000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-974800000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-902400000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
491889000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
554196000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
543028000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
612880000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56492000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34054000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23022000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11961000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
79514000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
46015000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-79514000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-46015000
CY2024Q1 us-gaap Interest Expense
InterestExpense
55000
CY2023Q1 us-gaap Interest Expense
InterestExpense
40000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
7256000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
5076000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-87000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-147000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7114000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4889000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-72400000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41126000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-974000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
470000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-73374000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40656000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-72400000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41126000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85213200
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85213200
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69438890
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69438890
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-72400000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-41126000
CY2024Q1 sndx Depreciation And Related Adjustment
DepreciationAndRelatedAdjustment
3000
CY2023Q1 sndx Depreciation And Related Adjustment
DepreciationAndRelatedAdjustment
3000
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3821000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3967000
CY2024Q1 sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
244000
CY2023Q1 sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
110000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8899000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6238000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2854000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2899000
CY2024Q1 sndx Increase Decrease In Collaboration Receivable Payable
IncreaseDecreaseInCollaborationReceivablePayable
315000
CY2023Q1 sndx Increase Decrease In Collaboration Receivable Payable
IncreaseDecreaseInCollaborationReceivablePayable
2082000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
6073000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69438890
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69438890
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
0
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1152000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3707000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6709000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-9174000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-83548000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39228000
CY2024Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
167385000
CY2023Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
61585000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
67986000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
81500000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-99399000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19915000
CY2024Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
309000
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
196000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1859000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2278000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2168000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2474000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-180779000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16839000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
295611000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
74471000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
114832000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57632000
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. We were incorporated in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delaware</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2005. We base our operations in Waltham, Massachusetts and we operate in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> segment. References in these notes to condensed consolidated financial statements to “Syndax,” “the Company,” “we,” “us” or “our” refer to Syndax Pharmaceuticals, Inc. and its wholly owned subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-9174000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-83548000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39228000
CY2024Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
167385000
CY2023Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
61585000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
67986000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
81500000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-99399000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19915000
CY2024Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
309000
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
196000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1859000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2278000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2168000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2474000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-180779000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16839000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
295611000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
74471000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
114832000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57632000
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Syndax Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. We were incorporated in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delaware</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2005. We base our operations in Waltham, Massachusetts and we operate in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> segment. References in these notes to condensed consolidated financial statements to “Syndax,” “the Company,” “we,” “us” or “our” refer to Syndax Pharmaceuticals, Inc. and its wholly owned subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s condensed consolidated financial statements.</span></p>
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85213200
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85213200
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s condensed consolidated financial statements.</span></p>
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-72400000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41126000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-72400000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-72400000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-41126000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41126000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-72400000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41126000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-72400000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-72400000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-41126000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41126000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85213200
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85213200
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69438890
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69438890
CY2024Q1 sndx Refundable Fee Payble
RefundableFeePayble
6100000
CY2024Q1 sndx Payment For Fully Refundable Fee
PaymentForFullyRefundableFee
6100000
CY2024Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2024Q1 sndx Refundable Fee Payble
RefundableFeePayble
6100000
CY2024Q1 sndx Payment For Fully Refundable Fee
PaymentForFullyRefundableFee
6100000
CY2024Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
428043000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
756000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
427287000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
304916000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
257000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
40000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
305133000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
467449000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6238000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
470000
CY2023Q1 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
196000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2278000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1076000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
888000
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
428043000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
756000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
427287000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
304916000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
257000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
40000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
305133000
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
1817000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
807000
CY2024Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
1513000
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1227000
CY2024Q1 sndx Prepaid Subscriptions
PrepaidSubscriptions
689000
CY2023Q4 sndx Prepaid Subscriptions
PrepaidSubscriptions
769000
CY2024Q1 sndx Prepaid State And Local Taxes
PrepaidStateAndLocalTaxes
399000
CY2023Q4 sndx Prepaid State And Local Taxes
PrepaidStateAndLocalTaxes
264000
CY2024Q1 us-gaap Prepaid Rent
PrepaidRent
164000
CY2023Q4 us-gaap Prepaid Rent
PrepaidRent
163000
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
83000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4665000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3293000
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
1817000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
807000
CY2024Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
1513000
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1227000
CY2024Q1 sndx Prepaid Subscriptions
PrepaidSubscriptions
689000
CY2023Q4 sndx Prepaid Subscriptions
PrepaidSubscriptions
769000
CY2024Q1 sndx Prepaid State And Local Taxes
PrepaidStateAndLocalTaxes
399000
CY2023Q4 sndx Prepaid State And Local Taxes
PrepaidStateAndLocalTaxes
264000
CY2024Q1 us-gaap Prepaid Rent
PrepaidRent
164000
CY2023Q4 us-gaap Prepaid Rent
PrepaidRent
163000
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
83000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
63000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4665000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3293000
CY2024Q1 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
18110000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4567000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11172000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1642000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1450000
CY2024Q1 sndx Accrued Milestone Costs
AccruedMilestoneCosts
8000000
CY2023Q4 sndx Accrued Milestone Costs
AccruedMilestoneCosts
10000000
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
33395000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
39856000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41126000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
435505000
CY2024Q1 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
309000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1859000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-72400000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
491889000
CY2024Q1 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
18110000
CY2023Q4 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
16346000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4567000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11172000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1642000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1450000
CY2024Q1 sndx Accrued Milestone Costs
AccruedMilestoneCosts
8000000
CY2023Q4 sndx Accrued Milestone Costs
AccruedMilestoneCosts
10000000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1076000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
888000
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
33395000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
39856000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8899000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6238000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8899000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6238000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
554196000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8899000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-974000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8899000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6238000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8899000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6238000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
554196000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8899000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-974000
CY2024Q1 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
309000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1859000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-72400000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
491889000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
467449000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6238000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
470000
CY2023Q1 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
196000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2278000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41126000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
435505000
CY2024Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
0
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
0
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-055053-index-headers.html Edgar Link pending
0000950170-24-055053-index.html Edgar Link pending
0000950170-24-055053.txt Edgar Link pending
0000950170-24-055053-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sndx-20240331.htm Edgar Link pending
sndx-20240331.xsd Edgar Link pending
sndx-ex31_1.htm Edgar Link pending
sndx-ex31_2.htm Edgar Link pending
sndx-ex32_1.htm Edgar Link pending
sndx-20240331_htm.xml Edgar Link completed